OncoZenge AB

As of June 30, 2026, OncoZenge AB carries a market capitalization of 84.78M, placing it among publicly traded companies globally. Its enterprise value stands at 91.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

OncoZenge AB's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, OncoZenge AB has 14.05M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 13.35, and the price-to-book ratio stands at 8.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 15.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 91.53M versus a market cap of 84.78M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, OncoZenge AB maintains a current ratio of 0.51, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.50, indicating elevated leverage, while an interest coverage ratio of -34.59 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OncoZenge AB posted a negative return on equity (ROE) of -255.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -131.13, reflecting losses generated across the asset base.

As of the close on October 23, 2026, OncoZenge AB's stock has declined approximately 29.86% over the past 52 weeks. The 50-day moving average sits at 3.75, while the 200-day moving average is 4.87.

Over the twelve months ended June 30, 2026, OncoZenge AB generated 5.84M in revenue and converted that into -25.29M in net income, yielding earnings per share of -1.96. EBITDA reached -24.60M, while operating income came in at -24.60M.

As of June 30, 2026, OncoZenge AB holds 749,000.00 in cash and equivalents against 7.50M in total debt, resulting in a net debt position of 6.75M. Total book value stands at 9.80M, with working capital of -4.65M providing operational flexibility.

OncoZenge AB produced -20.65M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -421.16 and net profit margin of -433.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -26.49: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.88, meaning OncoZenge AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

OncoZenge AB's most recent stock split took place on September 1, 2026 with a 500:599 split ratio.

As of June 30, 2026, OncoZenge AB has an Altman Z-Score of -8.38, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.